| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649041112 |
ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg, 12 |
01/01/2021 |
49.71 |
678.89 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649041124 |
ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg, 24 |
01/01/2021 |
99.41 |
1357.81 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649040130 |
ANUSOl-HC® (Hydrocortisone Cream, USP) 2.5%, 30gm |
01/01/2021 |
11.16 |
152.47 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649024141 |
AZASAN® (Azathioprine Tablets, USP) 100mg, 100ct |
01/01/2021 |
62.61 |
855.04 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649023141 |
AZASAN® (Azathioprine Tablets, USP) 75mg, 100ct |
01/01/2021 |
140.42 |
1917.88 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649020175 |
MOVIPREP® (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate & Ascorbic Acid for Oral Solution), 1 Kit |
01/01/2021 |
6.72 |
118.75 |
09/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649055102 |
RELISTOR® (methylnaltrexone bromide) 12mg/0.6mL, vial |
01/01/2021 |
9.85 |
134.52 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649055103 |
RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, 7ct |
01/01/2021 |
68.94 |
941.59 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649055107 |
RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, vial |
01/01/2021 |
9.85 |
134.52 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649055204 |
RELISTOR® (methylnaltrexone bromide) PFS 8 mg/0.4mL, 7ct |
01/01/2021 |
68.94 |
941.59 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649015090 |
RELISTOR® (methylnaltrexone bromide) Tablets 150mg, 90ct |
01/01/2021 |
147.74 |
2017.75 |
03/10/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649065103 |
UCERIS® (budesonide) Rectal Aerosol, Foam, two 54 ml Canisters, 2 mg/actuation |
01/01/2021 |
39.91 |
705.09 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649030103 |
XIFAXAN® (rifaximin) 200mg Tablets, 30ct |
01/01/2021 |
52.96 |
723.32 |
07/24/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649030303 |
XIFAXAN® (rifaximin) 550mg Tablets HUD 6 cards of 10, 60ct Card |
01/01/2021 |
201.89 |
2757.48 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649030302 |
XIFAXAN® (rifaximin) 550mg Tablets, 60ct |
01/01/2021 |
201.89 |
2757.48 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000027 |
Sandoz Inc. |
03/31/2021 |
61314014410 |
BRIMONIDINE TAR 0.15% 10ML |
01/20/2021 |
26.35 |
306.62 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Sandoz is engaged with CMS in ongoing discussions on the Drug Source Type for this product. Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. All information is provided by Sandoz Inc. to the best of our knowledge at the time of submission. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000027 |
Sandoz Inc. |
03/31/2021 |
61314014415 |
BRIMONIDINE TAR 0.15% 15ML |
01/20/2021 |
39.52 |
459.95 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Sandoz is engaged with CMS in ongoing discussions on the Drug Source Type for this product. Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. All information is provided by Sandoz Inc. to the best of our knowledge at the time of submission. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000027 |
Sandoz Inc. |
03/31/2021 |
61314014405 |
BRIMONIDINE TAR 0.15% 5ML |
01/20/2021 |
13.18 |
153.35 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Sandoz is engaged with CMS in ongoing discussions on the Drug Source Type for this product. Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. All information is provided by Sandoz Inc. to the best of our knowledge at the time of submission. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000092 |
Santarus, Inc. |
03/31/2021 |
68012025820 |
CYCLOSET® (bromocriptine mesytate tablets) 0.8 mg tablets, 200 ct |
01/01/2021 |
70.24 |
959.30 |
04/30/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2021 |
70257012611 |
VARIZIG, single dose vial of 125 IU in 1.2mL (inner vial) |
02/01/2021 |
88.40 |
1892.54 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
None |
1306.34 |
1185.00 |
2012 |
682.50 |
None |
NDC is a non-saleable unit.
Varizig introduced to the market in 2012 as lyophilized powder. Current formulation is liquid. Patent Exp. Date: N/A (Biologic status) |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2021 |
70257012651 |
VARIZIG, single dose vial of 125 IU in 1.2mL (outer carton) |
02/01/2021 |
88.40 |
1892.54 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
None |
1306.34 |
1185.00 |
2012 |
682.50 |
None |
Varizig introduced to the market in 2012 as lyophilized powder. Current formulation is liquid. Patent Exp. Date: N/A (Biologic status) |
| Rx0000086 |
Seattle Genetics, Inc. |
03/31/2021 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
01/01/2021 |
335.00 |
8927.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Office of Statewide Health Planning and Development's ("OSHPD") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to OSHPD, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-S blank because they are not applicable to this product. |
| Rx0000086 |
Seattle Genetics, Inc. |
09/30/2021 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
07/01/2021 |
348.00 |
9275.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Office of Statewide Health Planning and Development's ("OSHPD") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to OSHPD, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-S blank because they are not applicable to this product. |
| Rx0000086 |
Seattle Genetics, Inc. |
12/31/2021 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
12/30/2021 |
425.00 |
9700.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Healthcare Access and Information ("HCAI") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product. |
| Rx0000121 |
Secura Bio, Inc. |
06/30/2021 |
71779011502 |
Copiktra 15 mg oral capsule, 56 capsules per package |
04/25/2021 |
1348.04 |
14964.65 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2021 |
71779011502 |
Copiktra 15 mg oral capsule, 56 capsules per package |
11/16/2021 |
1481.50 |
16446.15 |
01/10/2032 |
Single Source Drug |
328 |
None |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
06/30/2021 |
71779012502 |
Copiktra 25 mg oral capsule, 56 capsules per package |
04/25/2021 |
1348.04 |
14964.65 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2021 |
71779012502 |
Copiktra 25 mg oral capsule, 56 capsules per package |
11/16/2021 |
1481.50 |
16446.15 |
01/10/2032 |
Single Source Drug |
1570 |
None |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
03/31/2021 |
00078065006 |
Farydak 10 mg oral capsule, 6 capsules per package |
02/01/2021 |
1058.03 |
11745.21 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
06/30/2021 |
00078065006 |
Farydak 10 mg oral capsule, 6 capsules per package |
04/25/2021 |
2337.30 |
14082.51 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
03/31/2021 |
00078065106 |
Farydak 15 mg oral capsule, 6 capsules per package |
02/01/2021 |
1058.03 |
11745.21 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
06/30/2021 |
00078065106 |
Farydak 15 mg oral capsule, 6 capsules per package |
04/25/2021 |
2337.30 |
14082.51 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
03/31/2021 |
00078065206 |
Farydak 20 mg oral capsule, 6 capsules per package |
02/01/2021 |
1058.03 |
11745.21 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
06/30/2021 |
00078065206 |
Farydak 20 mg oral capsule, 6 capsules per package |
04/25/2021 |
2337.30 |
14082.51 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000179 |
Slayback Pharma LLC |
06/30/2021 |
71225013001 |
Norethindrone acetate,ethyl estradiol cap and ferrous fumarate cap 1mg/20mcg |
05/18/2021 |
62.22 |
180.00 |
None |
Innovator Multiple Source Drug |
966 |
None |
Price was revised due to the market dynamics. |
None |
Price was revised due to the market dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000149 |
Strongbridge Biopharma plc |
03/31/2021 |
71090000101 |
Keveyis (dichlorphenamide) oral tablet, 50mg, Bottle of 100 |
01/18/2021 |
2046.17 |
22714.54 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/12/2016 |
Taro Pharmaceuticals Industries |
8500000 |
None |
None |
13650.00 |
13650.00 |
2015 |
13650.00 |
None |
None |
| Rx0000149 |
Strongbridge Biopharma plc |
09/30/2021 |
71090000101 |
Keveyis (dichlorphenamide) oral tablet, 50mg, Bottle of 100 |
09/17/2021 |
2248.74 |
24963.28 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/12/2016 |
Taro Pharmaceuticals Industries |
8500000 |
None |
None |
13650.00 |
13650.00 |
2015 |
13650.00 |
None |
None |
| Rx0000001 |
SUN PHARMACEUTICALS |
12/31/2021 |
47335017795 |
ILUMYA Subcutaneous Solution Prefilled Syringe100 MG/ML PFS |
11/02/2021 |
1572.40 |
15487.40 |
02/17/2031 |
Single Source Drug |
22870 |
None |
Increased cost of production & distribution
Increased sales & marketing expenses
Competitive pressure |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000001 |
SUN PHARMACEUTICALS |
06/30/2021 |
47335030383 |
Odomzo Sonidegib Cap 200mg 30ct |
04/01/2021 |
593.43 |
12462.02 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2021 |
27505000405 |
Apokyn Subcutaneous Solution 5 Cartridge 30 MG/3ML |
09/09/2021 |
461.56 |
6231.06 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/09/2020 |
US Worldmeds |
None |
1 |
Information regarding the purchase of the USWM CNS product line can be found in press releases, however, information regarding specific product pricing is not available. |
5500.00 |
5290.00 |
2011 |
846.00 |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2021 |
27505000401 |
Apokyn Subcutaneous Solution Single Cartridge 30 MG/3ML |
09/09/2021 |
92.31 |
1246.21 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/09/2020 |
US Worldmeds |
None |
1 |
Information regarding the purchase of the USWM CNS product line can be found in press releases, however, information regarding specific product pricing is not available. |
1100.00 |
1058.00 |
2011 |
169.20 |
None |
NDC 27505000401 is the inner level of a multi-level package. As such it is not listed separately on the FDA NDC Directory, it is instead included in the package description of NDC 2705000405. Supernus only markets the 27505000405 NDC. |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772012101 |
Oxtellar XR 150mg X 100, capsule |
01/01/2021 |
42.91 |
758.10 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772012201 |
Oxtellar XR 300mg X 100, capsule |
01/01/2021 |
59.62 |
1053.21 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772012301 |
Oxtellar XR 600mg X 100, capsule |
01/01/2021 |
109.15 |
1928.32 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010330 |
Trokendi XR 100mg X 30, capsule |
01/01/2021 |
47.96 |
847.32 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010301 |
Trokendi XR 100mg X100, capsule |
01/01/2021 |
159.87 |
2824.42 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010430 |
Trokendi XR 200mg X 30, capsule |
01/01/2021 |
65.61 |
1159.09 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010401 |
Trokendi XR 200mg X100, capsule |
01/01/2021 |
218.69 |
3863.60 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010130 |
Trokendi XR 25mg X 30, capsule |
01/01/2021 |
18.58 |
328.31 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010101 |
Trokendi XR 25mg X100, capsule |
01/01/2021 |
61.90 |
1094.38 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010230 |
Trokendi XR 50mg X 30, capsule |
01/01/2021 |
24.21 |
427.65 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010201 |
Trokendi XR 50mg X100, capsule |
01/01/2021 |
80.69 |
1425.54 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2021 |
27505011130 |
XADAGO TAB, 100MG 30CT |
09/09/2021 |
63.32 |
967.88 |
03/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/09/2020 |
US Worldmeds |
None |
1 |
Information regarding the purchase of the USWM CNS product line can be found in press releases, however, information regarding specific product pricing is not available. |
839.11 |
780.57 |
2017 |
730.19 |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2021 |
27505011030 |
XADAGO TAB, 50MG 30CT |
09/09/2021 |
63.32 |
967.88 |
03/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/09/2020 |
US Worldmeds |
None |
1 |
Information regarding the purchase of the USWM CNS product line can be found in press releases, however, information regarding specific product pricing is not available. |
839.11 |
780.57 |
2017 |
730.19 |
None |
None |